openPR Logo
Press release

Primary Sclerosing Cholangitis Market to Reach USD 2.5 Billion by 2034

08-26-2025 11:22 AM CET | Health & Medicine

Press release from: Exactitude Consultancy

Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis (PSC) is a rare, chronic, progressive liver disease characterized by inflammation and scarring of the bile ducts, which ultimately leads to cirrhosis, liver failure, and, in many cases, the need for liver transplantation. Although the exact cause remains unclear, PSC has strong associations with autoimmune disorders and inflammatory bowel disease (IBD). The growing global prevalence of liver disorders, improved diagnostic techniques, and increased research into rare diseases have placed PSC in the spotlight of pharmaceutical innovation and healthcare policy.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71127

In recent years, the market has witnessed increasing R&D investments, drug pipeline expansion, and rising awareness about rare diseases. As healthcare systems and biopharma companies focus on orphan drug development, PSC is becoming a critical area for clinical research. The next decade is set to witness significant developments in treatment options and market growth.

Market Overview
The Primary Sclerosing Cholangitis market size was valued at USD 1.1 billion in 2024 and is expected to reach USD 2.5 Billion by 2034, growing at a CAGR of 8.5% during 2025-2034.

Key Highlights:
• Market Size 2024: USD 1.1 Billion
• Forecast 2034: USD 2.5 Billion
• CAGR (2025-2034): 8.5%
• Key Growth Drivers: Rise in rare disease research funding, orphan drug designation incentives, liver transplantation demand, improved diagnostics
• Challenges: Lack of approved therapies, high treatment cost, clinical trial complexities, late-stage diagnosis
• Leading Players: Gilead Sciences, Intercept Pharmaceuticals, AbbVie, Novartis, Bristol Myers Squibb, Dr. Falk Pharma, Zydus Lifesciences

The lack of curative therapies represents both a challenge and an opportunity. Currently, no FDA-approved medication specifically targets PSC, although ursodeoxycholic acid and liver transplantation remain common management strategies. The strong R&D pipeline for PSC, supported by global orphan drug policies, is expected to drive market expansion through the next decade.

Segmentation Analysis
The PSC market can be segmented into product types, treatment approaches, technology, end-use, and applications.
By Product:
• Ursodeoxycholic Acid (UDCA)
• Immunosuppressants
• Corticosteroids
• Bile Acid Derivatives
• Others (experimental therapies)

By Platform:
• Biologics
• Small Molecules
• Combination Therapies

By Technology:
• Drug Development & Discovery Platforms
• Biomarker Identification
• Imaging & Diagnostic Technologies

By End Use:
• Hospitals
• Specialty Clinics
• Research & Academic Institutes

By Application:
• Liver Transplantation
• Symptom Management (pruritus, fatigue, jaundice)
• Disease Progression Monitoring
• Clinical Research/Trials

Segmentation Summary:
Biologics and novel small molecules are leading innovation in PSC treatment pipelines, with multiple clinical trials underway. Hospitals remain the largest end-user segment due to the complex nature of PSC management and the need for advanced infrastructure. Research institutions are also contributing significantly, given the ongoing demand for biomarker discovery and therapeutic development.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71127/primary-sclerosing-cholangitis-market

Regional Analysis
North America:
• The largest market, driven by advanced healthcare infrastructure, higher diagnosis rates, and strong biopharma presence.
• The U.S. leads in clinical trial activity and orphan drug approvals.
Europe:
• Significant growth due to rare disease funding programs and patient advocacy networks.
• Countries like Germany, France, and the UK play a central role in PSC research collaborations.
Asia-Pacific:
• Rapidly emerging due to increasing awareness of liver disorders, expanding healthcare expenditure, and pharmaceutical R&D.
• Japan and China are expected to lead regional growth.
Middle East & Africa:
• Slow adoption due to limited access to advanced diagnostics and treatments.
• However, rising investments in specialty healthcare and liver disease management are creating opportunities.
Latin America:
• Market growth is steady, led by Brazil and Mexico.
• The region is experiencing rising incidences of autoimmune-related liver disorders, driving research and diagnostic improvements.
Regional Summary:
North America and Europe dominate PSC research and treatment adoption, while Asia-Pacific is expected to deliver the highest growth rates through 2034 due to increasing government investments in rare disease management and growing clinical research activity.

Market Dynamics
Key Growth Drivers:
• Rising prevalence of autoimmune and liver-related disorders.
• Strong pipeline of investigational drugs with orphan drug status.
• Advances in imaging and biomarker-based diagnostics.
• Increased government support for rare disease research.
• Rising demand for liver transplantation.

Key Challenges:
• Absence of approved curative therapies.
• High cost of liver transplantation and limited donor availability.
• Regulatory complexities in clinical trial design for rare diseases.
• Limited awareness in emerging economies.

Latest Trends:
• Expansion of clinical trials focusing on FXR agonists, PPAR agonists, and immunotherapy approaches.
• Increasing collaborations between biotech firms and academic research institutions.
• Growing role of artificial intelligence (AI) in biomarker discovery and patient stratification.
• Patient advocacy groups influencing regulatory approvals and funding.
• Precision medicine approaches targeting genetic predispositions to PSC.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71127

Competitor Analysis
Major Players in the Market:
• Gilead Sciences, Inc. - Advancing FXR agonist therapies for liver diseases.
• Intercept Pharmaceuticals - Developing obeticholic acid-based treatments.
• AbbVie Inc. - Focused on autoimmune therapies with potential PSC applications.
• Novartis AG - Leveraging immunotherapy and biologics expertise.
• Bristol Myers Squibb (BMS) - Strong pipeline for immunomodulators.
• Dr. Falk Pharma GmbH - Specializing in gastrointestinal and hepatology products.
• Zydus Lifesciences Ltd. - Expanding portfolio of liver disease-related drugs.
Competitive Summary:
The competitive landscape is highly R&D-driven, with a focus on clinical trials for orphan-designated therapies. Companies are leveraging collaborations, licensing agreements, and partnerships with academic centers to accelerate innovation. Market growth will depend on successful drug approvals, patient adoption, and healthcare reimbursement policies.

Conclusion
The Primary Sclerosing Cholangitis (PSC) market, though rare, represents a growing frontier in hepatology and rare disease management. With market size expected to expand significantly between 2024 and 2034 at a CAGR of 8.5%, opportunities abound for pharmaceutical innovators, healthcare providers, and research institutions.

While the market faces hurdles such as high treatment costs and the lack of approved curative therapies, the robust pipeline of novel drugs, increased funding for rare diseases, and strong advocacy efforts are poised to reshape the treatment landscape. North America and Europe will continue to lead in terms of innovation and adoption, but Asia-Pacific will provide the fastest growth opportunities in the coming decade.

Key Takeaways:
• PSC market growth will be fueled by orphan drug designations and clinical pipeline expansion.
• Biologics and small molecules are central to next-generation treatments.
• Regional disparities remain, but awareness and government support are bridging gaps.
• Competitive intensity will increase as top pharma players advance late-stage clinical trials.
The outlook for the PSC market is cautiously optimistic, with the next decade likely to witness the first approved therapies, transforming patient care and creating new commercial opportunities.

This report is also available in the following languages : Japanese (原発性硬化性胆管炎市場), Korean (원발성 경화성 담관염 시장), Chinese (原发性硬化性胆管炎市场), French (Marché de la cholangite sclérosante primitive), German (Markt für primär sklerosierende Cholangitis), and Italian (Mercato della colangite sclerosante primitiva), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/reports/71127/primary-sclerosing-cholangitis-market#request-a-sample

Our More Reports:

Adult-onset Still Disease Market
https://exactitudeconsultancy.com/reports/71305/adult-onset-still-disease-market

Axial Spondyloarthritis Market
https://exactitudeconsultancy.com/reports/71307/axial-spondyloarthritis-market

Birch Allergy Market
https://exactitudeconsultancy.com/reports/71309/birch-allergy-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Sclerosing Cholangitis Market to Reach USD 2.5 Billion by 2034 here

News-ID: 4159617 • Views:

More Releases from Exactitude Consultancy

Cell Therapy Manufacturing Market to Reach USD 28.4 Billion by 2034, Growing at 13.9% CAGR
Cell Therapy Manufacturing Market to Reach USD 28.4 Billion by 2034, Growing at …
Introduction Cell therapy has emerged as a transformative pillar of modern medicine, offering the potential to repair, replace, or regenerate damaged tissues and organs. From CAR-T cell therapies for oncology to stem cell therapies for regenerative medicine, the field is redefining treatment paradigms across oncology, neurology, cardiology, and rare diseases. As clinical pipelines expand and more therapies achieve regulatory approval, demand for efficient and scalable cell therapy manufacturing has surged. Specialized technologies
Despite safety concerns, adavosertib exhibits early antitumor activity in uterine serous carcinoma
Despite safety concerns, adavosertib exhibits early antitumor activity in uterin …
Uterine serous carcinoma (USC) is a rare but highly aggressive subtype of endometrial cancer, accounting for less than 10% of endometrial cancer cases but contributing to a disproportionately high mortality rate. It is often diagnosed at advanced stages, making it difficult to treat with conventional methods. Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72873 In recent years, the treatment landscape has expanded beyond chemotherapy and surgery to include targeted therapies,
Market for Catheter-Related Bloodstream Infections: Overview, Therapies, and Important Players | Exactitude Consultancy
Market for Catheter-Related Bloodstream Infections: Overview, Therapies, and Imp …
Catheter-related bloodstream infections (CRBSIs) are among the most common and serious complications associated with intravascular catheters used in hospitals and long-term care settings. These infections can lead to prolonged hospital stays, increased healthcare costs, and higher mortality rates. With the rising use of central venous catheters, particularly among critically ill patients, oncology cases, and those requiring long-term intravenous therapy, the global demand for effective prevention and treatment solutions is growing
ADC Technology Market to Reach USD 33.7 Billion by 2034, Growing at 13.2% CAGR
ADC Technology Market to Reach USD 33.7 Billion by 2034, Growing at 13.2% CAGR
Introduction Antibody-drug conjugates (ADCs) represent one of the most innovative breakthroughs in oncology, combining the target specificity of monoclonal antibodies with the cytotoxic potency of chemotherapeutic agents. By delivering highly toxic payloads directly to cancer cells, ADCs minimize systemic toxicity and enhance therapeutic efficacy. As cancer incidence rises worldwide and the limitations of conventional chemotherapy become more evident, ADC technology is gaining momentum. With advancements in linker chemistry, payload design, and next-generation

All 5 Releases


More Releases for PSC

PSC (Primary Sclerosing Cholangitis) Patient Pool Analysis Market to Reach USD 2 …
Primary Sclerosing Cholangitis (PSC) is a rare but severe chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and increased risk of cirrhosis and cancer. With no definitive cure available, management strategies focus on slowing disease progression, alleviating symptoms, and improving patient quality of life. As awareness grows and diagnostic capabilities advance, the PSC patient pool analysis market is becoming increasingly vital for
Harlingen PSC Products at CIMT 2023 - Specifications and Industry Applications
Founded in 1989 by China Machine Tool & Tool Builders' Association, CIMT is one of the 4 prestigious international machine tool shows together with EMO, IMTS, JIMTOF. With the steady improving of influence, CIMT has become an important site of advanced technology communication and business trading. Along with the continuous lift of international standing and influence, CIMT has become an important place for exchange and trade of advanced global manufacturing technology,
Primary Sclerosing Cholangitis (PSC) Market Research Report, Growth Forecast 202 …
This research study on "Primary Sclerosing Cholangitis (PSC) market" reports offers the comparative assessment of Primary Sclerosing Cholangitis (PSC) market and consist of Historical data, Significance, statistical data, size & share, Market Price & Demand, Business overview, Market Analysis By Product and Market Trends by Key Players. This Primary Sclerosing Cholangitis (PSC) Market is Segmented in two type on the basis of type of materials and end-users. It has global
PSC Hands-Free Safety Tools Range 2019
PSC is India’s largest hands-free safety tools store that enables you to carry out tasks in the oilfield without getting your hands close to the pinch and crush points. This year we have exported these safety tools to over 15 countries including Nigeria, Mongolia, Kazakhstan, USA, Burma, Canada, Denmark, Vietnam, Singapore, UAE and others. Progressive companies that look at all possible ways to mitigate risks to hand injuries in the oilfield
Quality Management Software Market - Present growth dynamics 2025 | Hewlett-Pack …
Quality Management Software Market: Overview The global quality management software market is witnessing a substantial rise, thanks to the increasing uptake of quality management tools in enterprises due to their dynamic business models. The escalating adoption of quality management software by med-sized businesses is prime factor behind this tremendous growth of this market. Over the coming years, the worldwide market is projected to experience a tremendous rise in the demand for quality
Anti-Trafficking Bill Overbroad And Disproportionate; Should Be Referred To PSC
Responding to the passage of The Trafficking of Persons (Prevention, Protection and Rehabilitation) Bill, 2018 by the Lok Sabha yesterday, Asmita Basu, Programmes Director, said, “It is commendable that the Indian government is taking trafficking in persons seriously. However, if the Bill is enacted in its present form, it will put adults who engage in consensual sex work, at risk of human rights violations. The bill has several provisions that are